Scholars@Duke
Stephen Greene

Stephen Greene

Associate Professor of Medicine
Medicine, Cardiology
Manage Profile
Embed Profile Data

Selected Publications

Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure.

Journal Article JAMA Cardiol · July 1, 2024 IMPORTANCE: Kidney health has received increasing focus as part of comprehensive heart failure (HF) treatment efforts. However, the occurrence of clinically relevant kidney outcomes in contemporary populations with HF has not been well studied. OBJECTIVE: ... Full text Open Access Link to item Cite

Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure.

Journal Article Am J Cardiovasc Drugs · July 2024 Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care system ... Full text Link to item Cite

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

Journal Article Metabolism · June 4, 2024 The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associ ... Full text Link to item Cite

Role of telemedicine in the management of obesity: State-of-the-art review.

Journal Article Obes Rev · June 2024 Obesity is a worsening public health epidemic that remains challenging to manage. Obesity substantially increases the risk of cardiovascular diseases and presents a significant financial burden on the healthcare system. Digital health interventions, specif ... Full text Link to item Cite

Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trial.

Journal Article Eur J Heart Fail · June 2024 AIMS: The PARACOR-19 randomized controlled trial (RCT) was designed to examine the effects of sacubitril/valsartan on markers of cardiac injury, inflammation, structure, and function among patients who have recovered from acute coronavirus disease 2019 (CO ... Full text Link to item Cite

Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study

Journal Article International Journal of Cardiology: Cardiovascular Risk and Prevention · June 1, 2024 Background: Based on available data from randomized clinical trials, patients with heart failure with reduced ejection fraction (HFrEF) and worsening HF events (WHFE) have substantial disease burden and poor outcomes. WHFE clinical outcome data in non-clin ... Full text Cite

On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.

Journal Article Eur J Heart Fail · May 15, 2024 AIM: The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought ... Full text Link to item Cite

Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.

Journal Article Eur J Heart Fail · May 2024 AIM: Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all-cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney ... Full text Link to item Cite

Impact of Insurance Status and Region on Angiotensin Receptor-Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations.

Journal Article JACC Heart Fail · May 2024 BACKGROUND: An angiotensin receptor-neprilysin inhibitor (ARNI) is the preferred renin-angiotensin system (RAS) inhibitor for heart failure with reduced ejection fraction (HFrEF). Among eligible patients, insurance status and prescriber concern regarding o ... Full text Link to item Cite

Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study.

Journal Article JACC Heart Fail · April 7, 2024 BACKGROUND: Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss have not been well characterized nati ... Full text Link to item Cite

Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy.

Journal Article JACC Heart Fail · April 6, 2024 BACKGROUND: Little is known regarding differences in cause-specific costs between heart failure (HF) with ejection fraction (EF) ≤40% vs >40%, and potential cost implications of sodium glucose co-transporter 2 inhibitor (SGLT2i) therapy. OBJECTIVES: This s ... Full text Link to item Cite

Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart Failure.

Journal Article JACC Heart Fail · March 25, 2024 BACKGROUND: U.S. nationwide estimates of the proportion of patients newly diagnosed with heart failure with reduced ejection fraction (HFrEF) eligible for quadruple medical therapy, and the associated benefits of rapid implementation, are not well characte ... Full text Link to item Cite

Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.

Journal Article Cardiol Rev · March 2024 Various pharmacotherapies exist for heart failure with preserved ejection fraction (HFpEF), but with unclear comparative efficacy. We searched EMBASE, Medline, and Cochrane Library from inception through August 2021 for all randomized clinical trials in HF ... Full text Link to item Cite

Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure.

Journal Article JAMA Cardiol · March 1, 2024 IMPORTANCE: The Centers for Medicare & Medicaid Services (CMS) Bundled Payments for Care Improvement (BPCI) program was launched in 2013 with a goal to improve care quality while lowering costs to Medicare. OBJECTIVE: To compare changes in the quality and ... Full text Link to item Cite

Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.

Journal Article Am J Cardiovasc Drugs · March 2024 BACKGROUND: Recent evidence suggests that acetazolamide may be beneficial as an adjunctive diuretic therapy in patients with acute decompensated heart failure (HF). We aim to pool all the studies conducted until now and provide updated evidence regarding t ... Full text Link to item Cite

Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.

Journal Article Circ Heart Fail · March 2024 BACKGROUND: The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) found no significant difference in all-cause mortality or hospitalization among patients randomized to a strategy of torsemide versus furosemide follo ... Full text Link to item Cite

Use of natriuretic peptides and echocardiography for diagnosing heart failure.

Journal Article Eur J Heart Fail · March 2024 AIMS: International guidelines have recommended the use of echocardiography and natriuretic peptides (NP) testing in the diagnostic evaluation of heart failure (HF) for more than 10 years. However, real-world utilization of these diagnostic tests in the US ... Full text Link to item Cite

Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry.

Journal Article J Card Fail · February 2024 BACKGROUND: Patients hospitalized with heart failure (HF) and diabetes mellitus (DM) are at risk for worsening clinical status. Little is known about the frequency of therapeutic changes during hospitalization. We characterized the use of medical therapies ... Full text Link to item Cite

Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure.

Journal Article JAMA Cardiol · July 1, 2024 IMPORTANCE: Kidney health has received increasing focus as part of comprehensive heart failure (HF) treatment efforts. However, the occurrence of clinically relevant kidney outcomes in contemporary populations with HF has not been well studied. OBJECTIVE: ... Full text Open Access Link to item Cite

Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure.

Journal Article Am J Cardiovasc Drugs · July 2024 Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care system ... Full text Link to item Cite

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

Journal Article Metabolism · June 4, 2024 The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associ ... Full text Link to item Cite

Role of telemedicine in the management of obesity: State-of-the-art review.

Journal Article Obes Rev · June 2024 Obesity is a worsening public health epidemic that remains challenging to manage. Obesity substantially increases the risk of cardiovascular diseases and presents a significant financial burden on the healthcare system. Digital health interventions, specif ... Full text Link to item Cite

Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trial.

Journal Article Eur J Heart Fail · June 2024 AIMS: The PARACOR-19 randomized controlled trial (RCT) was designed to examine the effects of sacubitril/valsartan on markers of cardiac injury, inflammation, structure, and function among patients who have recovered from acute coronavirus disease 2019 (CO ... Full text Link to item Cite

Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study

Journal Article International Journal of Cardiology: Cardiovascular Risk and Prevention · June 1, 2024 Background: Based on available data from randomized clinical trials, patients with heart failure with reduced ejection fraction (HFrEF) and worsening HF events (WHFE) have substantial disease burden and poor outcomes. WHFE clinical outcome data in non-clin ... Full text Cite

On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.

Journal Article Eur J Heart Fail · May 15, 2024 AIM: The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought ... Full text Link to item Cite

Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.

Journal Article Eur J Heart Fail · May 2024 AIM: Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all-cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney ... Full text Link to item Cite

Impact of Insurance Status and Region on Angiotensin Receptor-Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations.

Journal Article JACC Heart Fail · May 2024 BACKGROUND: An angiotensin receptor-neprilysin inhibitor (ARNI) is the preferred renin-angiotensin system (RAS) inhibitor for heart failure with reduced ejection fraction (HFrEF). Among eligible patients, insurance status and prescriber concern regarding o ... Full text Link to item Cite

Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study.

Journal Article JACC Heart Fail · April 7, 2024 BACKGROUND: Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss have not been well characterized nati ... Full text Link to item Cite

Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy.

Journal Article JACC Heart Fail · April 6, 2024 BACKGROUND: Little is known regarding differences in cause-specific costs between heart failure (HF) with ejection fraction (EF) ≤40% vs >40%, and potential cost implications of sodium glucose co-transporter 2 inhibitor (SGLT2i) therapy. OBJECTIVES: This s ... Full text Link to item Cite

Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart Failure.

Journal Article JACC Heart Fail · March 25, 2024 BACKGROUND: U.S. nationwide estimates of the proportion of patients newly diagnosed with heart failure with reduced ejection fraction (HFrEF) eligible for quadruple medical therapy, and the associated benefits of rapid implementation, are not well characte ... Full text Link to item Cite

Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.

Journal Article Cardiol Rev · March 2024 Various pharmacotherapies exist for heart failure with preserved ejection fraction (HFpEF), but with unclear comparative efficacy. We searched EMBASE, Medline, and Cochrane Library from inception through August 2021 for all randomized clinical trials in HF ... Full text Link to item Cite

Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure.

Journal Article JAMA Cardiol · March 1, 2024 IMPORTANCE: The Centers for Medicare & Medicaid Services (CMS) Bundled Payments for Care Improvement (BPCI) program was launched in 2013 with a goal to improve care quality while lowering costs to Medicare. OBJECTIVE: To compare changes in the quality and ... Full text Link to item Cite

Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.

Journal Article Am J Cardiovasc Drugs · March 2024 BACKGROUND: Recent evidence suggests that acetazolamide may be beneficial as an adjunctive diuretic therapy in patients with acute decompensated heart failure (HF). We aim to pool all the studies conducted until now and provide updated evidence regarding t ... Full text Link to item Cite

Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.

Journal Article Circ Heart Fail · March 2024 BACKGROUND: The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) found no significant difference in all-cause mortality or hospitalization among patients randomized to a strategy of torsemide versus furosemide follo ... Full text Link to item Cite

Use of natriuretic peptides and echocardiography for diagnosing heart failure.

Journal Article Eur J Heart Fail · March 2024 AIMS: International guidelines have recommended the use of echocardiography and natriuretic peptides (NP) testing in the diagnostic evaluation of heart failure (HF) for more than 10 years. However, real-world utilization of these diagnostic tests in the US ... Full text Link to item Cite

Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry.

Journal Article J Card Fail · February 2024 BACKGROUND: Patients hospitalized with heart failure (HF) and diabetes mellitus (DM) are at risk for worsening clinical status. Little is known about the frequency of therapeutic changes during hospitalization. We characterized the use of medical therapies ... Full text Link to item Cite

Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.

Journal Article JAMA Cardiol · February 1, 2024 IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). OBJECTIVES: To compare clinical characteristics and treatment outcomes of tors ... Full text Link to item Cite

Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF.

Journal Article ESC Heart Fail · February 2024 AIMS: Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline-directed medical therapy (GDMT) regarding the sequen ... Full text Link to item Cite

Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.

Journal Article Am J Med · February 2024 Cardiovascular outcomes trials of sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated consistent signals of benefit in terms of both prevention and treatment of heart failure (HF), in patients with and without type 2 diabetes (T2D). In res ... Full text Link to item Cite

Temporal Trends in Substance Use and Cardiovascular Disease-Related Mortality in the United States.

Journal Article J Am Heart Assoc · January 16, 2024 BACKGROUND: There are limited data on substance use (SU) and cardiovascular disease (CVD)-related mortality trends in the United States. We aimed to evaluate SU+CVD-related deaths in the United States using the Centers for Disease Control and Prevention Wi ... Full text Link to item Cite

Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure.

Journal Article Prog Cardiovasc Dis · 2024 Despite robust scientific evidence and strong guideline recommendations, there remain significant gaps in initiation and dose titration of guideline-directed medical therapy (GDMT) for heart failure (HF) among eligible patients. Reasons surrounding these g ... Full text Link to item Cite

Treatment patterns of patients with worsening heart failure with reduced ejection fraction

Journal Article ESC Heart Failure · January 1, 2024 Aims: Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease-modifying therapy. CHART-HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and without WHFE. Method ... Full text Cite

Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials

Journal Article Current Heart Failure Reports · January 1, 2024 Purpose of Review: End stage kidney disease can be a slow process and it may be challenging to achieve required follow-up for sufficient events. Therefore, a surrogate kidney endpoint, such as estimated glomerular filtration rate (eGFR) slope maybe attract ... Full text Cite

Bio-adrenomedullin: A weak biomarker for a STRONG patient

Journal Article European Journal of Heart Failure · January 1, 2024 Full text Cite

Endpoint adjudication in cardiovascular clinical trials.

Journal Article Eur Heart J · December 7, 2023 Endpoint adjudication (EA) is a common feature of contemporary randomized controlled trials (RCTs) in cardiovascular medicine. Endpoint adjudication refers to a process wherein a group of expert reviewers, known as the clinical endpoint committee (CEC), ve ... Full text Link to item Cite

Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF.

Conference Am Heart J · November 2023 BACKGROUND: An 11-factor random forest model has been developed among ambulatory heart failure (HF) patients for identifying potential wild-type amyloidogenic TTR cardiomyopathy (wtATTR-CM). The model has not been evaluated in a large sample of patients ho ... Full text Open Access Link to item Cite

Frailty and Its Implications in Heart Failure with Reduced Ejection Fraction: Impact on Prognosis and Treatment.

Journal Article Cardiol Clin · November 2023 Frailty affects half of all patients with heart failure with reduced ejection fraction (HFrEF) and carries a ∼2-fold increased risk of mortality. The relationship between frailty and HFrEF is bidirectional, with one condition exacerbating the other. Parado ... Full text Link to item Cite

Comparison of 30-day Readmission Rates and Inpatient Cardiac Procedures for Weekday Versus Weekend Hospital Admissions for Heart Failure.

Journal Article J Card Fail · October 2023 BACKGROUND: Whether the timing of hospital presentation impacts care delivery and clinical outcomes for patients hospitalized for heart failure (HF) remains a matter of debate. In this study, we examined all-cause and HF-specific 30-day readmission rates f ... Full text Link to item Cite

Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors.

Journal Article Am J Cardiol · October 1, 2023 Sacubitril/valsartan improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with angiotensin-converting enzyme inhibitors (ACEis). However, data on postdischarge outcomes in renin-angiotensin system inhibitor (RASi ... Full text Link to item Cite

Hospital at Home as a Treatment Strategy for Worsening Heart Failure.

Journal Article Circ Heart Fail · October 2023 Hospital at home (HaH) is an innovative care model that may be particularly suited for heart failure (HF). Outpatient visits and inpatient care have been the 2 traditional settings for HF care, yet may not match the social and medical needs of patients at ... Full text Link to item Cite

Association of Chronic Renal Insufficiency with Inhospital Outcomes in Primary Heart Failure Hospitalizations (Insights from the National Inpatient Sample 2004 to 2018).

Journal Article Am J Cardiol · September 1, 2023 Chronic kidney disease (CKD) is a major co-morbidity in patients with heart failure (HF). There are limited contemporary data characterizing the clinical profile, inhospital outcomes, and resource use in patients hospitalized for HF with co-morbid CKD. We ... Full text Link to item Cite

Artificial intelligence and heart failure: A state-of-the-art review.

Journal Article Eur J Heart Fail · September 2023 Heart failure (HF) is a heterogeneous syndrome affecting more than 60 million individuals globally. Despite recent advancements in understanding of the pathophysiology of HF, many issues remain including residual risk despite therapy, understanding the pat ... Full text Link to item Cite

Sex differences in long-term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines-Heart Failure registry.

Journal Article Eur J Heart Fail · September 2023 AIMS: Sex differences in long-term outcomes following hospitalization for heart failure (HF) across ejection fraction (EF) subtypes are not well described. In this study, we evaluated the risk of mortality and rehospitalization among males and females acro ... Full text Link to item Cite

Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3.

Journal Article J Am Coll Cardiol · August 8, 2023 Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline ... Full text Link to item Cite

Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3.

Journal Article J Am Coll Cardiol · August 8, 2023 Despite the availability of lifesaving guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), there remain major gaps in utilization of these therapies among eligible patients. Simultaneous with these gaps in qu ... Full text Link to item Cite

Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction.

Journal Article JACC Heart Fail · August 2023 BACKGROUND: Initiation of evidence-based medications for patients with heart failure with reduced ejection fraction (HFrEF) during hospitalization in contemporary practice is unknown. OBJECTIVES: This study characterized opportunities for and achievement o ... Full text Link to item Cite

An Individual Patient-Level Meta-Analysis of Ischemic Versus Nonischemic Cardiomyopathy and Trajectory of Decongestion in Patients With Acute Decompensated Heart Failure.

Journal Article Am J Cardiol · August 1, 2023 Data are limited regarding the impact of ischemic cardiomyopathy (ICM) or non-ICM (NICM) on the trajectory of in-hospital decongestion among patients with acute decompensated heart failure (ADHF). Therefore, we aimed to assess the course of decongestion am ... Full text Link to item Cite

Patterns of Referral and Postdischarge Utilization of Cardiac Rehabilitation Among Patients Hospitalized With Heart Failure: An Analysis From the GWTG-HF Registry.

Journal Article Circulation. Heart failure · August 2023 BackgroundCoverage for cardiac rehabilitation (CR) for patients with heart failure with reduced ejection fraction was expanded in 2014, but contemporary referral and participation rates remain unknown.MethodsPatients hospitalized for hear ... Full text Open Access Cite

Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.

Journal Article Circulation · July 11, 2023 BACKGROUND: Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRAN ... Full text Link to item Cite

Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure.

Journal Article Eur J Heart Fail · July 2023 AIMS: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are effective across the spectrum of left ventricular ejection fraction (LVEF) in heart failure (HF); however, population-wide medication use in eligible patients remains suboptimal. We evaluated the ... Full text Link to item Cite

Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.

Journal Article JAMA Cardiol · July 1, 2023 IMPORTANCE: Clinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwid ... Full text Link to item Cite

Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.

Journal Article J Am Coll Cardiol · June 27, 2023 BACKGROUND: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on heart failure (HF) outcomes and cardiovascular (CV) death in patients with varying combinations of type 2 diabetes mellitus (T2DM), HF, and chronic kidney disease (CKD) are unc ... Full text Link to item Cite

Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials.

Journal Article Eur Heart J · June 1, 2023 Conventional randomized controlled trials (RCTs) can be expensive, time intensive, and complex to conduct. Trial recruitment, participation, and data collection can burden participants and research personnel. In the past two decades, there have been rapid ... Full text Link to item Cite

Quality of Care and Clinical Outcomes for Patients With Heart Failure at Hospitals Caring for a High Proportion of Black Adults: Get With The Guidelines-Heart Failure Registry.

Journal Article JAMA Cardiol · June 1, 2023 IMPORTANCE: Black adults with heart failure (HF) disproportionately experience higher population-level mortality than White adults with HF. Whether quality of care for HF differs at hospitals with high proportions of Black patients compared with other hosp ... Full text Link to item Cite

Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction.

Journal Article J Am Heart Assoc · May 16, 2023 Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated with these patients in US pra ... Full text Link to item Cite

Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials.

Journal Article J Card Fail · April 2023 BACKGROUND: Randomized controlled trials (RCTs) may report outcomes different from those prespecified on trial-registration websites, protocols and statistical analysis plans (SAPs). This study sought to investigate the prevalence and characteristics of he ... Full text Link to item Cite

Trajectory of Decongestion and Mortality in Young Adults with Acute Heart Failure.

Journal Article Curr Probl Cardiol · April 2023 Although the prevalence of HF in young adults (age <50 years) is increasing, there are limited data on the trajectory of decongestion and short-term outcomes in young adults with acute heart failure (AHF). We pooled patients from 3 randomized trials of AHF ... Full text Link to item Cite

Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.

Journal Article ESC Heart Fail · April 2023 AIMS: We investigated titration patterns of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs) and beta-blockers, quality of life (QoL) over 6 months, and associated 1 year outcome [all-cause mortality/heart failure (HF) ... Full text Link to item Cite

Quality of Care and Outcomes Among Patients Hospitalized for Heart Failure in Rural vs Urban US Hospitals: The Get With The Guidelines-Heart Failure Registry.

Journal Article JAMA Cardiol · April 1, 2023 IMPORTANCE: Prior studies have suggested patients with heart failure (HF) from rural areas have worse clinical outcomes. Contemporary differences between rural and urban hospitals in quality of care and clinical outcomes for patients hospitalized for HF re ... Full text Link to item Cite

Vericiguat for the treatment of heart failure with reduced ejection fraction.

Journal Article Expert Rev Cardiovasc Ther · April 2023 INTRODUCTION: Despite significant therapeutic advancements in heart failure with reduced ejection fraction (HFrEF), the residual risk of all-cause mortality and hospitalizations remains high among patients with HFrEF. Vericiguat is a novel oral soluble gua ... Full text Link to item Cite

Medication-Attributable Adverse Events in Heart Failure Trials.

Journal Article JACC. Heart failure · April 2023 BackgroundInitiation and up-titration of guideline-directed medical therapies (GDMTs) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal, in part because of concerns regarding tolerability and adverse events (AEs).Obje ... Full text Cite

Mechanisms of current therapeutic strategies for heart failure: more questions than answers?

Journal Article Cardiovasc Res · February 3, 2023 Heart failure (HF) is a complex, multifactorial and heterogeneous syndrome with substantial mortality and morbidity. Over the last few decades, numerous attempts have been made to develop targeted therapies that may attenuate the known pathophysiological p ... Full text Link to item Cite

Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study.

Journal Article ESC Heart Fail · February 2023 AIMS: Heart failure (HF) remains a major public health problem with increasing prevalence in China. This study evaluated the clinical performance and quality measures for HF management to identify gaps in the standardization of care for patients hospitaliz ... Full text Link to item Cite

In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.

Journal Article Circ Heart Fail · February 2023 BACKGROUND: Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is associated with greater long-term use in HFrEF. This study aim ... Full text Link to item Cite

Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure.

Journal Article Circ Heart Fail · February 2023 BACKGROUND: Heuristic biases are increasingly recognized, and potentially modifiable, contributors to patient care and outcomes. Left digit bias is a cognitive bias where continuous variables are categorized by their left-most digit. The impact of this heu ... Full text Link to item Cite

Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States.

Journal Article JACC Heart Fail · February 2023 BACKGROUND: In January 2021, vericiguat, a soluble guanylate cyclase stimulator, was approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of cardiovascular death and heart failure (HF) hospitalization among patients with a recent wors ... Full text Link to item Cite

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.

Journal Article JAMA · January 17, 2023 IMPORTANCE: Although furosemide is the most commonly used loop diuretic in patients with heart failure, some studies suggest a potential benefit for torsemide. OBJECTIVE: To determine whether torsemide results in decreased mortality compared with furosemid ... Full text Link to item Cite

Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review.

Journal Article J Card Fail · January 2023 Heart failure (HF) and end-stage kidney disease (ESKD) frequently coexist; 1 comorbidity worsens the prognosis of the other. HF is responsible for almost half the deaths of patients on dialysis. Despite patients' with ESKD composing an extremely high-risk ... Full text Link to item Cite

Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry.

Journal Article Eur J Heart Fail · January 2023 AIMS: Although atrial fibrillation (AF) frequently coexists with heart failure with preserved ejection fraction (HFpEF), few data are available evaluating AF-specific care patterns and post-discharge outcomes in patients hospitalized for HFpEF. We evaluate ... Full text Link to item Cite

Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.

Journal Article Circ Heart Fail · January 2023 BACKGROUND: Alignment between clinician-reported New York Heart Association (NYHA) class compared and patient-reported outcomes among patients hospitalized for heart failure is unclear. METHODS: ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritid ... Full text Link to item Cite

Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.

Journal Article JAMA Cardiol · January 1, 2023 IMPORTANCE: The expansion of sodium-glucose cotransporter-2 (SGLT-2) inhibitor use in patients with heart failure (HF) and left ventricular ejection fraction (LVEF) more than 40% following the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with ... Full text Link to item Cite

Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week.

Journal Article Journal of the American College of Cardiology · January 2023 Heart failure (HF) is a progressive disease characterized by variable durations of symptomatic stability often punctuated by episodes of worsening despite continued therapy. These periods of clinical worsening are increasingly recognized as a distinct phas ... Full text Cite

Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society.

Journal Article Prog Cardiovasc Dis · 2023 Diabetes Technology Society assembled a panel of clinician experts in diabetology, cardiology, clinical chemistry, nephrology, and primary care to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who ... Full text Link to item Cite

Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction.

Journal Article J Card Fail · December 2022 BACKGROUND: Differences between patients hospitalized for heart failure with reduced ejection fraction (HFrEF) vs HF with preserved EF (HFpEF) are not well-characterized, particularly as pertains to in-hospital decongestion and longitudinal patient-reporte ... Full text Link to item Cite

Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF.

Journal Article Am Heart J · December 2022 BACKGROUND: Heart Failure with Preserved Ejection Fraction (HFpEF) is a heterogenous disease with few therapies proven to provide clinical benefit. Machine learning can characterize distinct phenotypes and compare outcomes among patients with HFpEF who are ... Full text Link to item Cite

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe.

Journal Article Eur Heart J Suppl · December 2022 Diabetes and chronic kidney disease (CKD) are important comorbidities in patients with heart failure (HF) that can complicate the clinical management and have major implications for morbidity and mortality. In addition, the presence of these comorbidities, ... Full text Link to item Cite

Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis.

Journal Article Eur J Prev Cardiol · November 8, 2022 AIMS: There are several risk scores designed to predict mortality in patients with heart failure (HF). This study aimed to assess performance of risk scores validated for mortality prediction in patients with acute HF (AHF) and chronic HF. METHODS AND RESU ... Full text Link to item Cite

The need for increased pragmatism in cardiovascular clinical trials.

Journal Article Nat Rev Cardiol · November 2022 The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these 'explanatory' trial designs optimize conditions to test the efficacy and safety ... Full text Link to item Cite

Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database.

Journal Article Curr Probl Cardiol · November 2022 The trends of implantable cardioverter defibrillator (ICD) use in patients with a durable left ventricular assist device (LVAD) remain uncertain. We used the National Inpatient Sample to identify hospitalizations between 2009 and 2018 in which patients rec ... Full text Link to item Cite

Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019.

Journal Article JACC Heart Fail · November 2022 BACKGROUND: The U.S. population is aging with concurrent increases in heart failure (HF) burden. However, HF-related mortality trends among adults ≥75 years have not been investigated. OBJECTIVES: The purpose of this study was to assess the trends and regi ... Full text Link to item Cite

Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial.

Journal Article J Card Fail · October 2022 BACKGROUND: Death ascertainment can be challenging for pragmatic clinical trials that limit site follow-up activities to usual clinical care. METHODS AND RESULTS: We used blinded aggregate data from the ongoing ToRsemide comparison with furoSemide FOR Mana ... Full text Link to item Cite

National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey.

Journal Article Am Heart J · October 2022 BACKGROUND: Statins are a cornerstone guideline-directed medical therapy for secondary prevention of ischemic heart disease (IHD). However, recent temporal trends and disparities in statin utilization for IHD have not been well characterized. METHODS: This ... Full text Link to item Cite

Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial.

Journal Article Am Heart J · September 2022 BACKGROUND: Clinical guidelines recommend titration of angiotensin converting enzyme inhibitors (ACEi) and beta-blockers among patients with heart failure with reduced ejection fraction (HFrEF) to maximally tolerated doses. Patient characteristics associat ... Full text Link to item Cite

Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study.

Journal Article Am Heart J · September 2022 BACKGROUND: Patients with heart failure with reduced ejection fraction (HFrEF) and worsening HF events (WHFE) represent a distinct subset of patients with a substantial comorbidity burden, greater potential for intolerance to medical therapy, and high risk ... Full text Link to item Cite

Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019.

Journal Article JAMA Cardiol · September 1, 2022 IMPORTANCE: There are limited data on mortality trends in young adults with heart failure (HF). OBJECTIVE: To study the trends in HF-related mortality among young adults. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis used mortality ... Full text Link to item Cite

Contemporary Applications of Machine Learning for Device Therapy in Heart Failure.

Journal Article JACC Heart Fail · September 2022 Despite a better understanding of the underlying pathogenesis of heart failure (HF), pharmacotherapy, surgical, and percutaneous interventions do not prevent disease progression in all patients, and a significant proportion of patients end up requiring adv ... Full text Link to item Cite

Demographic and Regional Trends of Hypertrophic Cardiomyopathy-Related Mortality in the United States, 1999 to 2019.

Journal Article Circ Heart Fail · September 2022 BACKGROUND: Hypertrophic cardiomyopathy (HCM)-related mortality has been decreasing within the United States; however, persistent disparities in demographic subsets may exist. In this study, we assessed nationwide trends in mortality related to HCM among p ... Full text Link to item Cite

Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection Fraction.

Journal Article J Card Fail · August 2022 BACKGROUND: COVID-19 may negatively impact the prognosis of patients with chronic HFrEF and vice versa. METHODS: This study included 2 parallel analyses of patients in the United States who were in the TriNetX health database and who underwent polymerase c ... Full text Link to item Cite

Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.

Journal Article J Card Fail · July 2022 BACKGROUND: For patients hospitalized for heart failure with reduced ejection fraction (HFrEF), guidelines recommend optimization of medical therapy prior to discharge. The degree to which changes in medical therapy occur during hospitalizations for HFrEF ... Full text Link to item Cite

Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure.

Journal Article J Card Fail · June 2022 BACKGROUND: Worsening heart failure (HF) often requires hospitalization but in some cases may be managed in the outpatient or emergency department (ED) settings. The predictors and clinical significance of ED visits without admission vs hospitalization are ... Full text Link to item Cite

Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelines-Heart Failure registry.

Journal Article Eur J Heart Fail · June 2022 AIMS: To assess heart failure (HF) in-hospital quality of care and outcomes before and during the COVID-19 pandemic. METHODS AND RESULTS: Patients hospitalized for HF with ejection fraction (EF) <40% in the American Heart Association Get With The Guideline ... Full text Link to item Cite

Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Journal Article J Am Heart Assoc · May 17, 2022 Background Clinical prediction models have been developed for hospitalization for heart failure in type 2 diabetes. However, a systematic evaluation of these models' performance, applicability, and clinical impact is absent. Methods and Results We searched ... Full text Link to item Cite

Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction.

Journal Article Heart Fail Rev · May 2022 In clinical practice, many patients with heart failure with reduced ejection fraction (HFrEF) are either not prescribed guideline-directed medical therapies for which they are eligible or are prescribed therapies at sub-target doses. The objective of this ... Full text Link to item Cite

Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018.

Journal Article Circ Heart Fail · May 2022 BACKGROUND: Heart failure (HF) accounts for a significant proportion of morbidity, mortality, and health care costs among older adults in the United States. We evaluated trends in clinical outcomes and the economic burden of HF hospitalizations in older pa ... Full text Link to item Cite

Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018.

Journal Article JACC. Heart failure · May 2022 ObjectivesThe aim of this study was to assess trends in heart failure (HF) hospitalizations among young adults.BackgroundData are limited regarding clinical characteristics and outcomes of young adults hospitalized for HF.Methods ... Full text Cite

Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.

Journal Article J Card Fail · April 2022 BACKGROUND: The sodium-glucose cotransporter-2 (SGLT-2) inhibitors form the latest pillar in the management of heart failure with reduced ejection fraction (HFrEF) and appear to be effective across a range of patient profiles. There is increasing interest ... Full text Open Access Link to item Cite

Trends in Characteristics and Outcomes of Peripartum Cardiomyopathy Hospitalizations in the United States Between 2004 and 2018.

Journal Article Am J Cardiol · April 1, 2022 Data are limited on contemporary temporal trends in maternal characteristics and outcomes in hospitalized patients with peripartum cardiomyopathy (PC). We used the National Inpatient Sample database from January 1, 2004, to December 31, 2018, to identify P ... Full text Link to item Cite

Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.

Journal Article ESC Heart Fail · April 2022 AIMS: Recent trials have evaluated sodium-glucose co-transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI). METHODS AND RESULTS: Fragility index is defi ... Full text Link to item Cite

Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018.

Journal Article ESC Heart Fail · April 2022 AIMS: Hospitalization for heart failure (HF) constitutes a major healthcare and economic burden. Trends and characteristics of hospitalizations for HF for the recent years are not clear. We sought to determine the trends and characteristics of hospitalizat ... Full text Link to item Cite

Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.

Journal Article JACC Heart Fail · April 2022 OBJECTIVES: In this study, we sought to evaluate the association of frailty with the use of optimal guideline-directed medical therapy (GDMT) and outcomes in heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The burden of frailty in HFrEF i ... Full text Link to item Cite

Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.

Journal Article J Card Fail · March 2022 BACKGROUND: The comparative effectiveness of differing dosages of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) on clinical and patient-reported outcomes in clinical practice in the United States is unkn ... Full text Link to item Cite

Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.

Journal Article JACC Heart Fail · March 2022 OBJECTIVES: The authors sought to characterize associations between initiation of metformin and sulfonylurea therapy and clinical outcomes among patients with comorbid heart failure (HF) and diabetes (overall and by ejection fraction [EF] phenotype). BACKG ... Full text Open Access Link to item Cite

Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review.

Journal Article Circ Heart Fail · March 2022 BACKGROUND: Heart failure has a disproportionate burden on patients who are Black, Indigenous, and people of color (BIPOC), but not much is known about representation of these groups in randomized controlled trials (RCTs). We explored temporal trends in an ... Full text Link to item Cite

Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.

Journal Article Eur J Heart Fail · March 2022 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and qua ... Full text Link to item Cite

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.

Journal Article Cardiovasc Diabetol · February 5, 2022 BACKGROUND: There is uncertainty and limited data regarding initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors among patients hospitalized with acute heart failure (AHF). This systematic review and meta-analysis aim to establish the efficacy a ... Full text Link to item Cite

Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.

Journal Article J Card Fail · February 2022 BACKGROUND: Clinical practice guidelines support sustained use of renin-angiotensin-aldosterone-system (RAAS) inhibitors over time in heart failure with reduced ejection fraction, yet few data are available regarding the frequency, timing or predictors of ... Full text Link to item Cite

Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.

Journal Article JAMA Netw Open · February 1, 2022 This cross-sectional study evaluates the representation of women as authors of pivotal trials of novel cardiovascular drugs approved by the US Food and Drug Administration between 2008 and 2020. ... Full text Link to item Cite

Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018.

Journal Article Am Heart J · January 2022 AIM: To determine the trends in hospitalizations for heart failure (HF), acute myocardial infarction (AMI), and stroke in the United States (US). METHOD AND RESULTS: A retrospective analysis of the National Inpatient Sample weighted data between January 1, ... Full text Link to item Cite

Breaking Clinical Inertia in Heart Failure Management.

Journal Article Jt Comm J Qual Patient Saf · January 2022 Full text Link to item Cite

An evaluation of torsemide in patients with heart failure and renal disease.

Journal Article Expert Rev Cardiovasc Ther · January 2022 INTRODUCTION: Torsemide is a loop diuretic that inhibits the Na+/K+/2Cl- cotransporter type 2 in the thick ascending loop of Henle, leading to increased excretion of urinary sodium and chloride and associated diuresis. While furosemide remains the dominant ... Full text Link to item Cite

Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.

Journal Article Prog Cardiovasc Dis · 2022 Prior studies have reported improvements in population-level risk factor burden and cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a comprehensive assessment of the impact of polypills on CVD outcomes, mortality, adh ... Full text Link to item Cite

Leveraging “Big Data” for the Design and Execution of Clinical Trials

Chapter · January 1, 2022 Randomized clinical trials form the cornerstone of evidence-based medicine and are required to accurately determine cause-effect relationships and treatment effects of medical interventions. Nonetheless, contemporary clinical trials are becoming increasing ... Full text Cite

Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.

Journal Article JACC Heart Fail · December 2021 OBJECTIVES: The authors sought to investigate associations between sacubitril/valsartan adherence and clinical outcomes after hospitalization for heart failure with reduced ejection fraction (HFrEF). BACKGROUND: Sacubitril/valsartan improves outcomes in HF ... Full text Link to item Cite

Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.

Journal Article JAMA Cardiol · December 1, 2021 IMPORTANCE: The US Food and Drug Administration (FDA) expanded labeling for sacubitril/valsartan for use in individuals with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) lower than normal. The population-level implications of i ... Full text Link to item Cite

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Coll Cardiol · November 16, 2021 Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on ... Full text Link to item Cite

Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease.

Journal Article J Card Fail · November 2021 BACKGROUND: Greater variability in the estimated glomerular filtration rate (eGFR) is associated with higher mortality in patients with chronic kidney disease (CKD). Heart failure (HF) is common in CKD and may increase variability through changes in hemody ... Full text Link to item Cite

Drugs of Abuse and Heart Failure.

Journal Article J Card Fail · November 2021 Substance use is common among those with heart failure (HF) and is associated with worse clinical outcomes. Alcohol, tobacco, cannabis, and cocaine are commonly abused substances that can contribute to the development and worsening of HF. Heavy alcohol con ... Full text Link to item Cite

Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.

Journal Article Circ Heart Fail · November 2021 BACKGROUND: Diuretics are a mainstay therapy for the symptomatic treatment of heart failure. However, in contemporary US outpatient practice, the degree to which diuretic dosing changes over time and the associations with clinical outcomes and health care ... Full text Link to item Cite

Physical Functioning in Heart Failure With Preserved Ejection Fraction.

Journal Article J Card Fail · September 2021 Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent, yet interventions and therapies to improve outcomes remain limited. There has been increasing attention towards the impact of comorbidities and physical functioning (PF) on p ... Full text Link to item Cite

Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map.

Journal Article Eur J Heart Fail · September 2021 AIMS: To appraise meta-analytically determined effect of dietary interventions and nutritional supplements on heart failure (HF)-related outcomes, and create an evidence map to visualize the findings and certainty of evidence. METHODS AND RESULTS: Online d ... Full text Link to item Cite

Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial.

Journal Article Eur J Heart Fail · September 2021 AIMS: We assessed the effect of transitional care on patient-reported outcomes (PROs) in women and men hospitalized for heart failure. METHODS AND RESULTS: In this sex-specific analysis of a stepped wedge cluster randomized trial in Canada, the effect of a ... Full text Link to item Cite

Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.

Journal Article Circ Heart Fail · September 2021 BACKGROUND: Randomized controlled trials (RCTs) often target enrollment of patients with demographics and outcomes less representative of the broader population of interest. To provide context for the VICTORIA trial (Vericiguat Global Study in Subjects Wit ... Full text Link to item Cite

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Heart Assoc · August 17, 2021 Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real-world US practice ... Full text Link to item Cite

Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.

Journal Article ESC Heart Fail · August 2021 AIMS: Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. ... Full text Link to item Cite

Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.

Journal Article J Card Fail · August 2021 BACKGROUND: We investigated associations between timing of sacubitril/valsartan initiation and postdischarge adherence among patients hospitalized for heart failure with reduced ejection fraction (HFrEF). Clinical trials support initiation of sacubitril/va ... Full text Link to item Cite

Reply: Pragmatic Clinical Trials: The Big Picture.

Journal Article JACC Heart Fail · August 2021 Full text Link to item Cite

Kidney Function and Outcomes in Patients Hospitalized With Heart Failure.

Journal Article J Am Coll Cardiol · July 27, 2021 BACKGROUND: Few contemporary data exist evaluating care patterns and outcomes in heart failure (HF) across the spectrum of kidney function. OBJECTIVES: This study sought to characterize differences in quality of care and outcomes in patients hospitalized f ... Full text Link to item Cite

Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications.

Journal Article Curr Heart Fail Rep · June 2021 PURPOSE OF REVIEW: Multiple newer medications benefit patients with heart failure with reduced ejection fraction (HFrEF). While these therapies benefit the broad population with HFrEF, the efficacy and safety of these therapies have been less well characte ... Full text Link to item Cite

Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.

Journal Article JACC Heart Fail · May 2021 Randomized clinical trials are the foundation of evidence-based medicine and central to practice guidelines and patient care decisions. Nonetheless, randomized trials in heart failure (HF) populations have become increasingly difficult to conduct and are f ... Full text Link to item Cite

Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.

Journal Article JAMA Cardiol · May 1, 2021 IMPORTANCE: It is unclear how New York Heart Association (NYHA) functional class compares with patient-reported outcomes among patients with heart failure (HF) in contemporary US clinical practice. OBJECTIVE: To characterize longitudinal changes and concor ... Full text Link to item Cite

Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.

Journal Article JACC Heart Fail · May 2021 OBJECTIVES: The goal of this study was to evaluate differences in clinical and patient-reported outcomes between women and men hospitalized for acute HF. BACKGROUND: Among patients hospitalized for heart failure (HF), it is unclear if symptom burden, respo ... Full text Link to item Cite

Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure.

Journal Article Circ Heart Fail · April 2021 BACKGROUND: Hospitalization for heart failure (HF) is associated with increased risk of death among patients with chronic HF. The degree to which hospitalization for HF is a distinct biologic entity with independent prognostic value versus a marker of high ... Full text Link to item Cite

Trends in 30- and 90-Day Readmission Rates for Heart Failure.

Journal Article Circ Heart Fail · April 2021 BACKGROUND: The impact of hospital readmission reduction program (HRRP) on heart failure (HF) outcomes has been debated. Limited data exist regarding trends of HF readmission rates beyond 30 days from all-payer sources. The aim of this study was to investi ... Full text Link to item Cite

Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.

Journal Article Am Heart J · March 2021 Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate ... Full text Link to item Cite

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.

Journal Article Am Heart J · March 2021 In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, ... Full text Link to item Cite

Body surface area and medication dosing in patients with heart failure with reduced ejection fraction.

Journal Article Trends Cardiovasc Med · February 2021 Multiple medications are proven to reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), but data regarding personalized approaches to optimize medication dosing remain limited. Current treatment guidelines r ... Full text Link to item Cite

Impact of Atrial Fibrillation on In-Hospital Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation.

Journal Article J Cardiovasc Transl Res · February 2021 The association between atrial fibrillation (AF) and thromboembolic (TE) complications in left ventricular assist device (LVAD) recipients is controversial, and there is paucity of large-scale data evaluating the impact of AF on early outcomes after device ... Full text Link to item Cite

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.

Journal Article Am Heart J · February 2021 UNLABELLED: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with improved cardiovascular and kidney outcomes. However, the magnitude and potential heterogeneity of effect across patients with varying types of cardiometabolic and kidney ... Full text Link to item Cite

Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results.

Journal Article ESC Heart Fail · February 2021 AIMS: Discontinuation or non-publication of trials may hinder scientific progress and violates the commitment made to research participants. We sought to identify the prevalence of discontinuation and non-publication of heart failure (HF) clinical trials. ... Full text Link to item Cite

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.

Journal Article ESC Heart Fail · February 2021 AIMS: This study aimed to investigate the reporting of subgroup analyses in heart failure (HF) randomized controlled trials (RCTs) and to determine the strength and credibility of subgroup claims. METHODS AND RESULTS: All primary HF RCTs published in nine ... Full text Link to item Cite

Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis.

Journal Article ESC Heart Fail · February 2021 AIMS: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition, and tissue congestion manifested by oedema is not present in all patients. We compared clinical characteristics, exercise capacity, and outcomes in patients with HFp ... Full text Link to item Cite

Temporal trends in risk profiles among patients hospitalized for heart failure.

Journal Article Am Heart J · February 2021 BACKGROUND: Postdischarge mortality following hospitalization for heart failure with reduced ejection fraction (HFrEF) has remained high and unchanged over the past 2 decades, despite effective therapies for HFrEF. We aimed to explore whether these pattern ... Full text Link to item Cite

Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory.

Journal Article JACC Heart Fail · January 2021 The treatment of heart failure with reduced ejection fraction (HFrEF) has changed considerably over time, particularly with the sequential development of therapies aimed at antagonism of maladaptive biologic pathways, including inhibition of the sympatheti ... Full text Link to item Cite

Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America.

Journal Article J Card Fail · January 2021 Heart failure (HF) remains a leading cause of mortality and morbidity and a primary driver of health care resource use in the United States. As such, there continues to be much interest in the development and refinement of HF clinics that manage patients w ... Full text Link to item Cite

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF.

Journal Article J Am Heart Assoc · December 15, 2020 Background Ultrafiltration is not commonly used because of higher incidence of worsening renal function without improved decongestion. We examined differential outcomes of high versus low fluid removal and preserved versus reduced ejection fraction (EF) in ... Full text Open Access Link to item Cite

Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center.

Journal Article Am Heart J · December 2020 UNLABELLED: Smoking is associated with incident heart failure (HF), yet limited data are available exploring the association between smoking status and long-term outcomes in HF with reduced vs. preserved ejection fraction (i.e., HFrEF vs. HFpEF). METHODS: ... Full text Link to item Cite

In-hospital outcomes after bariatric surgery in patients with heart failure.

Journal Article Am Heart J · December 2020 Based on the largest publicly available all-payer inpatient database in the United States, this study sought to evaluate real-world outcomes after bariatric surgery among patients with heart failure. ... Full text Link to item Cite

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.

Journal Article ESC Heart Fail · December 2020 AIMS: We sought to conduct a meta-analysis regarding the safety and efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). METHODS AND RESULTS: MEDLINE, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were sear ... Full text Link to item Cite

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry.

Journal Article JAMA Cardiol · November 13, 2020 IMPORTANCE: In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Ad ... Full text Link to item Cite

In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States.

Journal Article JACC Heart Fail · November 2020 OBJECTIVES: This study sought to characterize in-hospital treatment patterns and associated patient outcomes among patients hospitalized for heart failure (HF) in U.S. clinical practice. BACKGROUND: Hospitalizations for HF are common and associated with po ... Full text Link to item Cite

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.

Journal Article JACC Heart Fail · October 2020 The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S ... Full text Link to item Cite

Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials.

Journal Article Circ Heart Fail · August 2020 BACKGROUND: Gender disparities in authorship of heart failure (HF) guideline citations and clinical trials have not been examined. METHODS: We identified authors of publications referenced in Class I Recommendations in United States (n=173) and European (n ... Full text Link to item Cite

Deaths in pulmonary hypertension: US location trends.

Journal Article BMJ Support Palliat Care · July 24, 2020 Full text Link to item Cite

Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.

Journal Article J Am Heart Assoc · June 2, 2020 Background In 1993, the US Food and Drug Administration established guidelines to increase diversity by sex and race/ethnicity of participants in clinical trials supporting novel drug approvals. In this study we investigated the 10-year trends of participa ... Full text Link to item Cite

Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.

Journal Article JAMA Cardiol · June 1, 2020 IMPORTANCE: Although age, sex, and race/ethnicity are important factors when generalizing the findings of clinical trials to routine practice, trends in the representation of these groups in contemporary acute coronary syndrome (ACS) trials are not well de ... Full text Link to item Cite

Trends in prevalence of comorbidities in heart failure clinical trials.

Journal Article Eur J Heart Fail · June 2020 AIMS: The primary objective of this systematic review was to estimate the prevalence and temporal changes in chronic comorbid conditions reported in heart failure (HF) clinical trials. METHODS AND RESULTS: We searched MEDLINE for HF trials enrolling more t ... Full text Link to item Cite

Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.

Journal Article JACC Heart Fail · June 2020 OBJECTIVES: The purpose of this study was to characterize the clinical profile, treatment patterns, and clinical outcomes of patients with comorbid diabetes mellitus (DM) and heart failure with reduced ejection fraction (HFrEF) in a contemporary, real-worl ... Full text Link to item Cite

Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study.

Journal Article J Card Fail · May 2020 BACKGROUND: Diastolic dysfunction (DD) is common and occurs at an earlier age among human immunodeficiency virus-infected (HIV+) individuals, but the mechanisms and consequences of DD among HIV+ individuals are unclear. METHODS AND RESULTS: The Characteriz ... Full text Link to item Cite

Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.

Journal Article Circ Heart Fail · May 2020 BACKGROUND: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide v ... Full text Link to item Cite

TEMPORAL TRENDS IN SEVERITY IN CLINICAL RISK PROFILES AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 24, 2020 Link to item Cite

Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.

Journal Article JAMA Cardiol · March 1, 2020 IMPORTANCE: There are major gaps in use of guideline-directed medical therapy (GDMT) for patients with heart failure (HF). Patient-reported data outlining patient goals and preferences associated with GDMT are not available. OBJECTIVE: To survey patients w ... Full text Link to item Cite

Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Journal Article Eur J Heart Fail · March 2020 AIMS: Left atrial (LA) mechanical function may play a significant role in the development and progression of heart failure with preserved ejection fraction (HFpEF). We performed a systematic review and meta-analysis to evaluate association of impaired LA f ... Full text Link to item Cite

Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?

Journal Article Am Heart J · February 2020 BACKGROUND: Cardiorespiratory fitness (CRF) is closely linked to health status and clinical outcomes in heart failure (HF) patients. We aimed to test whether biomarkers can reflect CRF and its change over time. METHODS: This post hoc analysis used data fro ... Full text Link to item Cite

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Journal Article Circulation · December 17, 2019 Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycem ... Full text Link to item Cite

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Journal Article JACC Heart Fail · November 2019 OBJECTIVES: This study sought to determine the degree to which U.S. patients enrolled in a heart failure (HF) trial represent patients in routine U.S. clinical practice according to race and sex. BACKGROUND: Black patients and women are frequently under-re ... Full text Link to item Cite

Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

Journal Article Can J Cardiol · September 2019 BACKGROUND: Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone. METHODS: The Aldosterone Targeted Neuroh ... Full text Link to item Cite

Watchman implantation in a patient with left atrial appendage thrombus.

Journal Article J Cardiovasc Electrophysiol · September 2019 Full text Link to item Cite

Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Coll Cardiol · May 21, 2019 BACKGROUND: Guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as tolerated. The degree to which titration occurs in contemporary U.S. pra ... Full text Link to item Cite

Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey.

Journal Article JACC Heart Fail · May 2019 OBJECTIVES: This study sought to determine clinician and scientist involvement in heart failure (HF) clinical research and to describe the challenges of conducting clinical trials in the United States. BACKGROUND: Improvements in the current capability, po ... Full text Link to item Cite

Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.

Journal Article J Cardiovasc Med (Hagerstown) · April 2019 BACKGROUND: The IRONOUT-HF trial previously demonstrated that oral iron supplementation minimally increased iron stores and did not improve exercise capacity in patients with heart failure with a reduced ejection fraction (HFrEF) and iron deficiency. METHO ... Full text Link to item Cite

Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.

Journal Article Eur J Heart Fail · March 2019 Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clinical practice guidelines recommend using the same target d ... Full text Link to item Cite

History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure.

Journal Article JACC. Heart failure · January 2019 ObjectivesThis study sought to characterize the course of decongestion among patients hospitalized for acute heart failure (AHF) by history of atrial fibrillation (AF) and/or atrial flutter (AFL).BackgroundAF/AFL and chronic heart failure ... Full text Cite

Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.

Journal Article JACC Heart Fail · January 2019 Patients with worsening heart failure with reduced ejection fraction (HFrEF) spend a large proportion of time in the hospital and other health care facilities. The benefits of guideline-directed medical therapy (GDMT) in the outpatient setting have been sh ... Full text Link to item Cite

Death: The Simple Clinical Trial Endpoint.

Journal Article Stud Health Technol Inform · 2019 Death, as a biological phenomenon, is well understood and a commonly employed endpoint for clinical trials. However, death identification and adjudication may be difficult for pragmatic clinical trials (PCT) that rely upon electronic health record and pati ... Link to item Cite

High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.

Conference J Am Heart Assoc · December 18, 2018 Background We sought to study the prevalence of high-sensitivity troponin and its association with cardiac structure and outcomes in ambulatory and hospitalized patients with heart failure with a preserved ejection fraction ( HF p EF ). Methods and Results ... Full text Link to item Cite

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Journal Article Lancet · October 27, 2018 BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ... Full text Link to item Cite

Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial.

Journal Article Am Heart J · October 2018 INTRODUCTION: Worsening renal function (WRF) can occur throughout a hospitalization for acute heart failure (HF). However, decongestion can be measured in different ways and the prognostic implications of WRF in the setting of different measures of deconge ... Full text Link to item Cite

Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review.

Journal Article JAMA Cardiol · October 1, 2018 IMPORTANCE: Despite the importance of age, sex, and race/ethnicity representativeness in clinical trials, limited data exist regarding the enrollment trends of these groups in contemporary heart failure (HF) trials. OBJECTIVE: To characterize the represent ... Full text Link to item Cite

Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.

Journal Article Eur J Heart Fail · October 2018 Contemporary clinical trials in heart failure (HF) enroll patients largely based on acuity of presentation, left ventricular ejection fraction (EF), and functional status. These trial programs variably employ certain enrichment criteria such as prior hospi ... Full text Link to item Cite

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Journal Article Circ Cardiovasc Qual Outcomes · October 2018 BACKGROUND: Globalization of clinical trials fosters inclusion of higher and lower income countries, but the influence of enrolling country income level on heart failure trial performance is unclear. This study sought to evaluate associations between enrol ... Full text Link to item Cite

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Journal Article Circulation · September 4, 2018 With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging, and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal tren ... Full text Link to item Cite

Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.

Journal Article Eur J Heart Fail · September 2018 AIM: To assess adverse outcomes attributable to non-cardiac co-morbidities and to compare their effects by left ventricular ejection fraction (LVEF) group [LVEF <50% (heart failure with reduced ejection fraction, HFrEF), LVEF ≥50% (heart failure with prese ... Full text Link to item Cite

Heart Failure Society of America Research Network Survey

Conference Journal of Cardiac Failure · August 2018 Full text Cite

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

Journal Article J Am Coll Cardiol · July 24, 2018 BACKGROUND: Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree to which gaps in medication use and dosing persi ... Full text Link to item Cite

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).

Journal Article Am J Cardiol · July 15, 2018 Patients with chronic heart failure with reduced ejection fraction (HFrEF) benefit from medical and device therapies targeting sudden cardiac death (SCD). Contemporary estimates of SCD risk after hospitalization for heart failure are limited. We describe t ... Full text Link to item Cite

Expanded algorithm for managing patients with acute decompensated heart failure.

Journal Article Heart Fail Rev · July 2018 Heart failure is a complex disease process, the manifestation of various cardiac and noncardiac abnormalities. General treatment approaches for heart failure have remained the same over the past decades despite the advent of novel therapies and monitoring ... Full text Link to item Cite

Home-Time After Discharge Among Patients Hospitalized With Heart Failure.

Journal Article J Am Coll Cardiol · June 12, 2018 BACKGROUND: Surveys of patients with cardiovascular disease have suggested that "home-time"-being alive and out of any health care institution-is a prioritized outcome. This novel measure has not been studied among patients with heart failure (HF). OBJECTI ... Full text Link to item Cite

The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.

Journal Article Eur J Heart Fail · June 2018 Although traditional renin-angiotensin system antagonists including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of cardiovascular disease (CVD), the pivotal PARADIGM-HF trial demonstrated tha ... Full text Link to item Cite

Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Journal Article Am Heart J · May 2018 BACKGROUND: Despite more than 200 years of clinical experience and a pivotal trial, recently published research has called into question the safety and efficacy of digoxin therapy in heart failure (HF). METHODS: HF-ACTION (ClinicalTrials.gov Number: NCT000 ... Full text Link to item Cite

Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.

Journal Article Eur J Heart Fail · April 2018 AIMS: The direct renin inhibitor, aliskiren, is known to reduce plasma renin activity (PRA), but whether the efficacy of aliskiren varies based on an individual's baseline PRA in patients hospitalized for heart failure (HF) is presently unknown. We charact ... Full text Link to item Cite

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Journal Article JACC Heart Fail · April 2018 OBJECTIVES: As the largest acute heart failure (AHF) trial conducted to date, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial database presented an opportunity to systematically describe the r ... Full text Link to item Cite

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Journal Article J Am Coll Cardiol · March 27, 2018 Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published ... Full text Link to item Cite

Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

Journal Article JAMA Cardiol · March 1, 2018 IMPORTANCE: Hospitalizations for worsening heart failure (WHF) represent an enormous public health and financial burden, with physicians, health systems, and payers placing increasing emphasis on hospitalization prevention. In addition, maximizing time out ... Full text Link to item Cite

Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial.

Journal Article Eur J Heart Fail · February 2018 AIMS: Troponin levels are commonly elevated among patients hospitalized for heart failure (HF), but the prevalence and prognostic significance of early post-discharge troponin elevation are unclear. This study sought to describe the frequency and prognosti ... Full text Link to item Cite

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Journal Article Eur J Heart Fail · February 2018 AIMS: Patients hospitalized for heart failure (HF) are at high risk for 30-day readmission. This study sought to examine the timings and causes of readmission within 30 days of an HF hospitalization. METHODS AND RESULTS: Timing and cause of readmission in ... Full text Link to item Cite

Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment.

Journal Article Curr Heart Fail Rep · February 2018 PURPOSE OF REVIEW: Clinical trial design and execution are evolving as increasingly important considerations with respect to the success of heart failure trials. The current review highlights temporal trends in characteristics of heart failure clinical tri ... Full text Link to item Cite

Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study.

Journal Article Int J Cardiol · December 1, 2017 BACKGROUND: Despite the burden of pre-clinical heart failure (HF) among diabetes mellitus (DM) patients, routine screening echocardiography is not currently recommended. We prospectively assessed risk prediction for HF/death of a screening strategy combini ... Full text Link to item Cite

Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Journal Article ESC Heart Fail · November 2017 Studies with angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) in patients with heart failure with preserved ejection fraction (HFpEF) have yielded inconsistent results. To conduct a systematic review and meta-analy ... Full text Link to item Cite

Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure.

Journal Article Card Fail Rev · November 2017 Acute Heart Failure (AHF) is a " multi-event disease" and hospitalisation is a critical event in the clinical course of HF. Despite relatively rapid relief of symptoms, hospitalisation for AHF is followed by an increased risk of death and re-hospitalisatio ... Full text Link to item Cite

Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.

Journal Article Circ Heart Fail · August 2017 BACKGROUND: The association between angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in patients with heart failure (HF) with reduced ejection fraction is uncertain. The objective of this study was t ... Full text Link to item Cite

Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).

Journal Article Am J Cardiol · July 1, 2017 Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post hoc analysis was performed using pooled data from the Diuretic Optimization Strategies Evaluation in ... Full text Link to item Cite

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Journal Article J Am Coll Cardiol · June 27, 2017 BACKGROUND: It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF survivors differ from those with more recent HF diagnoses. OBJECTIVES: The goal of this study was to evaluate the influence of HF chronicity on ac ... Full text Link to item Cite

Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?

Journal Article Can J Cardiol · June 2017 Despite the growing number of patients with heart failure with preserved ejection fraction (HFpEF) and event rates comparable with many cancers, there remain no pharmacologic agents definitively proven to improve patient outcomes. Although phase II trials ... Full text Link to item Cite

Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy.

Journal Article J Cardiovasc Med (Hagerstown) · April 2017 AIMS: This article describes an ongoing study investigating the safety and efficacy of ischemia-tolerant mesenchymal stem cell (MSC) therapy in patients with nonischemic heart failure and dysfunctional viable myocardium without scarring. This study will fo ... Full text Link to item Cite

Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Journal Article Eur J Heart Fail · April 2017 AIMS: Change in NT-proBNP level is a common surrogate endpoint in early phase heart failure (HF) trials, but whether this endpoint is influenced by atrial fibrillation/flutter (AFF) is unclear. METHODS AND RESULTS: This analysis included 1358 patients from ... Full text Link to item Cite

Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial.

Journal Article Am Heart J · April 2017 BACKGROUND: Although aerobic exercise improves quality of life as assessed by a disease-specific instrument in ambulatory HF patients with a reduced ejection fraction (EF), the impact of an exercise intervention on general health status has not been previo ... Full text Link to item Cite

Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.

Journal Article Nat Rev Cardiol · April 2017 Heart failure is a pressing worldwide public-health problem with millions of patients having worsening heart failure. Despite all the available therapies, the condition carries a very poor prognosis. Existing therapies provide symptomatic and clinical bene ... Full text Link to item Cite

ALTERNATING BUNDLE BRANCH BLOCK: CLINICAL CONSIDERATIONS

Conference Journal of the American College of Cardiology · March 2017 Full text Cite

Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.

Journal Article Circ Res · January 20, 2017 RATIONALE: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs shoul ... Full text Link to item Cite

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Journal Article JACC Heart Fail · January 2017 OBJECTIVES: This study sought to examine the relationships between in-hospital and post-discharge body weight changes and outcomes among patients hospitalized for acute heart failure (AHF). BACKGROUND: Body weight changes during and after hospitalization f ... Full text Link to item Cite

Country Income Level, Protocol Completion, and Trial Endpoints Among Patients With Acute Heart Failure: Insights From the ASCEND-HF Trial

Conference · 2017 Introduction: Globalization of clinical trials fosters inclusion of patients from higher and lower income countries. The influence of enrolling country income level on heart failure (HF) trial performance is unclear.Methods: Associations between country in ... Cite

Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.

Journal Article BMC Cardiovasc Disord · October 21, 2016 BACKGROUND: Insulin-like growth factor binding protein-7 (IGFBP-7) modulates the biological activities of insulin-like growth factor-1 (IGF-1). Previous studies demonstrated the prognostic value of IGFBP-7 and IGF-1 among patients with systolic heart failu ... Full text Link to item Cite

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Journal Article Circ Heart Fail · September 2016 BACKGROUND: Most international acute heart failure trials have failed to show benefit with respect to key end points. The impact of site enrollment and protocol execution on trial performance is unclear. METHODS AND RESULTS: We assessed the impact of varyi ... Full text Link to item Cite

Natriuretic peptide-guided management in heart failure.

Journal Article J Cardiovasc Med (Hagerstown) · August 2016 Heart failure is a clinical syndrome that manifests from various cardiac and noncardiac abnormalities. Accordingly, rapid and readily accessible methods for diagnosis and risk stratification are invaluable for providing clinical care, deciding allocation o ... Full text Link to item Cite

Role of omega-3 polyunsaturated fatty acids after acute coronary syndrome

Journal Article Giornale Italiano di Cardiologia · July 1, 2016 The role of omega-3 polyunsaturated fatty acids (PUFAs) in the secondary prevention of cardiovascular disease has recently been debated. The GISSI-Prevention trial demonstrated that supplementation with 1 g/day of eicosapentaenoic acid plus docosahexaenoic ... Cite

Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Journal Article JACC Heart Fail · June 2016 Heart failure (HF) is a major and increasing global public health problem. In Asia, aging populations and recent increases in cardiovascular risk factors have contributed to a particularly high burden of HF, with outcomes that are poorer than those in the ... Full text Link to item Cite

Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.

Journal Article Circ Heart Fail · May 2016 BACKGROUND: Dyspnea is the most common symptom among hospitalized patients with heart failure and represents a therapeutic target. However, the association between short-term dyspnea relief and postdischarge clinical outcomes and health-related quality of ... Full text Link to item Cite

Developing New Treatments for Heart Failure: Focus on the Heart.

Journal Article Circ Heart Fail · May 2016 Compared with heart failure (HF) care 20 to 30 years ago, there has been tremendous advancement in therapy for ambulatory HF with reduced ejection fraction with the use of agents that block maladaptive neurohormonal pathways. However, during the past decad ... Full text Link to item Cite

Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.

Journal Article Am J Cardiol · April 1, 2016 Serum osmolality may fluctuate with neurohormonal activation and in response to certain therapeutics in patients with heart failure (HF). The clinical relevance of osmolality in patients with HF has not been defined. In this post hoc analysis of the Effica ... Full text Link to item Cite

Trends in Heart Failure Clinical Trials From 2001-2012.

Journal Article J Card Fail · March 2016 BACKGROUND: A systematic assessment of the temporal trends in heart failure (HF) clinical trials is lacking. METHODS AND RESULTS: A total of 154 phase II-IV HF trials including 162,725 patients published from 2001 to 2012 in 8 high-impact-factor journals w ... Full text Link to item Cite

The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.

Journal Article Eur J Heart Fail · March 2016 AIMS: A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. METHODS AND RESULTS: A post-hoc analysis was performed of the ASCEND-HF trial. Th ... Full text Link to item Cite

Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).

Journal Article Am J Cardiol · February 15, 2016 In observational studies of patients hospitalized for heart failure (HHF), risk of death is highest immediately after discharge and decreases over time. It is unclear whether this population risk trajectory reflects (1) lowering of individual patient morta ... Full text Link to item Cite

Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction.

Journal Article Am J Cardiol · February 1, 2016 Clinical trials studying the efficacy of n-3 polyunsaturated fatty acids (PUFA) in reducing adverse events after acute myocardial infarction (AMI) have yielded conflicting results, and data regarding the influence of n-3 PUFA treatment after AMI in routine ... Full text Link to item Cite

Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.

Journal Article Heart Fail Rev · January 2016 Heart failure (HF) represents a global public health and economic problem associated with unacceptable rates of death, hospitalization, and healthcare expenditure. Despite available therapy, HF carries a prognosis comparable to many forms of cancer with a ... Full text Link to item Cite

[Role of omega-3 polyunsaturated fatty acids after acute coronary syndrome].

Journal Article G Ital Cardiol (Rome) · 2016 The role of omega-3 polyunsaturated fatty acids (PUFAs) in the secondary prevention of cardiovascular disease has recently been debated. The GISSI-Prevention trial demonstrated that supplementation with 1 g/day of eicosapentaenoic acid plus docosahexaenoic ... Full text Link to item Cite

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

Journal Article JAMA · December 1, 2015 IMPORTANCE: Worsening chronic heart failure (HF) is a major public health problem. OBJECTIVE: To determine the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic HF and reduced left ventr ... Full text Link to item Cite

Natriuretic peptide-guided management in heart failure.

Journal Article J Cardiovasc Med (Hagerstown) · November 7, 2015 Heart failure is a clinical syndrome that manifests from various cardiac and noncardiac abnormalities. Accordingly, rapid and readily accessible methods for diagnosis and risk stratification are invaluable for providing clinical care, deciding allocation o ... Full text Link to item Cite

Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells.

Journal Article J Am Coll Cardiol · November 3, 2015 Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small, leading to uncertainty as to whether they will translate into ... Full text Link to item Cite

In-hospital worsening heart failure.

Journal Article Eur J Heart Fail · November 2015 Acute worsening heart failure (WHF) is seen in a sizable portion of patients hospitalized for heart failure, and is increasingly being recognized as an entity that is associated with an adverse in-hospital course. WHF is generally defined as worsening hear ... Full text Link to item Cite

Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial.

Journal Article Eur J Heart Fail · October 2015 AIMS: Previous reports have provided conflicting data regarding the relationship between length of stay (LOS) and subsequent readmission risk among patients hospitalized for heart failure (HF). METHODS AND RESULTS: We performed a post-hoc analysis of the E ... Full text Link to item Cite

Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations.

Journal Article Heart Fail Clin · October 2015 Hospitalized heart failure (HHF) patients carry a prognosis comparable to many cancers and constitute more than 1 million hospital admissions annually in the United States. To date, North Americans have comprised a minority of those included in prior hospi ... Full text Link to item Cite

Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study.

Journal Article Heart Fail Clin · October 2015 Although the prognosis of ambulatory heart failure (HF) has improved dramatically there have been few advances in the management of acute HF (AHF). Despite regional differences in patient characteristics, background therapy, and event rates, AHF clinical t ... Full text Open Access Link to item Cite

Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012).

Journal Article Am J Cardiol · July 15, 2015 Device uptake and development have progressed over the last decade, but few quantitative data exist examining the overall operating characteristics and temporal trends of these clinical trials. We performed a systematic analysis of all cardiovascular devic ... Full text Link to item Cite

Site selection for heart failure clinical trials in the USA.

Journal Article Heart Fail Rev · July 2015 There are more than 1 million primary hospitalizations for heart failure (HF) annually in the USA alone, and post-discharge outcomes remain persistently poor despite available therapies and quality improvement initiatives. Recent international randomized c ... Full text Link to item Cite

Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.

Journal Article Heart Fail Rev · July 2015 With one possible exception, the last decade of clinical trials in hospitalized heart failure (HHF) patients has failed to demonstrate improvement in long-term clinical outcomes. This trend necessitates a need to evaluate optimal drug development strategie ... Full text Link to item Cite

Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial.

Journal Article Eur J Heart Fail · June 2015 AIMS: This study sought to investigate regional variation in clinical characteristics, therapy utilization, and post-discharge outcomes among patients hospitalized for heart failure (HHF) enrolled in the multinational ASTRONAUT (Aliskiren Trial on Acute He ... Full text Link to item Cite

Population risk prediction models for incident heart failure: a systematic review.

Journal Article Circ Heart Fail · May 2015 BACKGROUND: The prevalence of heart failure is expected to significantly rise unless high-risk patients are effectively screened and appropriate, cost-effective prevention interventions are implemented. METHODS AND RESULTS: We performed a systematic review ... Full text Link to item Cite

The vulnerable phase after hospitalization for heart failure.

Journal Article Nat Rev Cardiol · April 2015 Despite available therapy, mortality and readmission rates within 60-90 days of discharge for patients hospitalized with heart failure (HF) approach 15% and 30%, respectively. This early postdischarge period has been termed the 'vulnerable phase' and accou ... Full text Link to item Cite

The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure.

Journal Article J Card Fail · March 2015 There are >1 million hospitalizations for heart failure (HF) in the United States annually. After discharge, 25% of these patients are rehospitalized within 30 days, and 30% are dead within 1 year. To date, all trials in patients with acute HF (AHF) have f ... Full text Link to item Cite

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.

Journal Article JACC Heart Fail · February 2015 The prevalence of patients with concomitant heart failure (HF) and diabetes mellitus (DM) continues to increase with the general aging of the population. In patients with chronic HF, prevalence of DM is 24% compared with 40% in those hospitalized with wors ... Full text Link to item Cite

Water and sodium in heart failure: a spotlight on congestion.

Journal Article Heart Fail Rev · January 2015 Despite all available therapies, the rates of hospitalization and death from heart failure (HF) remain unacceptably high. The most common reasons for hospital admission are symptoms related to congestion. During hospitalization, most patients respond well ... Full text Link to item Cite

Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.

Journal Article Eur J Heart Fail · January 2015 AIMS: The purpose of this study was to determine the prognostic significance and associated clinical profile of early post-discharge N-terminal pro-B-type natriuretic peptide (NT-proBNP) trajectory among patients hospitalized for worsening chronic heart fa ... Full text Link to item Cite

Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.

Journal Article Expert Rev Cardiovasc Ther · 2015 Congestion is the most common reason for admissions and readmissions for heart failure (HF). The vast majority of hospitalized HF patients appear to respond readily to loop diuretics, but available data suggest that a significant proportion are being disch ... Full text Link to item Cite

Hemoconcentration-guided diuresis in heart failure.

Journal Article Am J Med · December 2014 One quarter of patients hospitalized for heart failure are readmitted within 30 days, perhaps related to ineffective decongestion. Limited data exist guiding the extent and duration of diuresis in patients hospitalized for heart failure. The objective of t ... Full text Link to item Cite

Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

Journal Article Am J Cardiol · December 1, 2014 We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤40%, with specific focus on gender, race, and renal function base ... Full text Link to item Cite

Lipids, statins, and clinical outcomes in heart failure: rethinking the data.

Journal Article Heart Fail Rev · November 2014 Lower serum lipid levels are paradoxically predictive of poor clinical outcomes in hospitalized and ambulatory patients with heart failure (HF). In large randomized controlled trials, statins did not demonstrate an overall mortality benefit in chronic HF p ... Full text Link to item Cite

Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Journal Article Am J Cardiol · September 1, 2014 Despite the well-established benefits of mineralocorticoid receptor agonists (MRAs) in heart failure with reduced ejection fraction, safety concerns remain in patients with concomitant diabetes mellitus (DM) because of common renal and electrolyte abnormal ... Full text Link to item Cite

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.

Journal Article Am Heart J · August 2014 Recent international phase III clinical trials of novel therapies for hospitalized heart failure (HHF) have failed to improve the unacceptably high postdischarge event rate. These large studies have demonstrated notable geographic and site-specific variati ... Full text Link to item Cite

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.

Journal Article Circ Heart Fail · May 2014 BACKGROUND: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. METHODS AND ... Full text Link to item Cite

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Journal Article J Am Coll Cardiol · April 1, 2014 Heart failure is a global pandemic affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in both the United States and Europe. Although the outcomes for ambulatory HF patients with a reduced eject ... Full text Link to item Cite

Endpoints for diuresis: are we there yet?

Journal Article J Am Coll Cardiol · March 4, 2014 Full text Link to item Cite

Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.

Journal Article Heart Fail Rev · March 2014 There are over 1 million hospitalizations for heart failure (HF) annually in the United States alone, and a similar number has been reported in Europe. Recent clinical trials investigating novel therapies in patients with hospitalized HF (HHF) have been ne ... Full text Link to item Cite

The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.

Journal Article JACC Heart Fail · December 2013 OBJECTIVES: The purpose of this study was to characterize the relationship between heart rate and post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction (EF) in sinus rhythm. BACKGROUND: A reduction ... Full text Link to item Cite

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Journal Article Eur J Heart Fail · December 2013 AIMS: Haemoconcentration has been studied as a marker of decongestion in patients with hospitalization for heart failure (HHF). We describe the relationship between haemoconcentration, worsening renal function, post-discharge outcomes, and clinical and lab ... Full text Link to item Cite

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Journal Article Am J Cardiol · December 1, 2013 Serum magnesium levels may be impacted by neurohormonal activation, renal function, and diuretics. The clinical profile and prognostic significance of serum magnesium level concentration in patients hospitalized for heart failure (HF) with reduced ejection ... Full text Link to item Cite

Quadrupole Anisotropy in Dihadron Azimuthal Correlations in CentralCollisions at

Journal Article Physical Review Letters · November 20, 2013 Full text Cite

The immunological axis in heart failure: importance of the leukocyte differential.

Journal Article Heart Fail Rev · November 2013 The important role of the immune system and inflammation in the pathophysiology of heart failure (HF) is becoming increasingly appreciated. We have reviewed the prognostic significance of under-recognized aspects of the leukocyte differential in HF, includ ... Full text Link to item Cite

Anticoagulation in heart failure: current status and future direction.

Journal Article Heart Fail Rev · November 2013 Despite therapeutic advances, patients with worsening heart failure (HF) requiring hospitalization have unacceptably high post-discharge mortality and re-admission rates soon after discharge. Evidence suggests a hypercoagulable state is present in patients ... Full text Link to item Cite

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Journal Article Eur Heart J · October 2013 AIMS: The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ... Full text Link to item Cite

Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.

Journal Article Eur J Heart Fail · June 2013 AIMS: Human stresscopin is a corticotropin-releasing factor (CRF) type 2 receptor (CRFR2) selective agonist and a member of the CRF peptide family. Stimulation of CRFR2 improves cardiac output and left ventricular ejection fraction (LVEF) in patients with ... Full text Link to item Cite

Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.

Journal Article Eur J Heart Fail · May 2013 AIMS: In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or hospitalization due to heart failure (HF) in several pre-specified high-risk subgroups of HF patients, but data on protocol-specified 2-year outcomes were not presented. I ... Full text Link to item Cite

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Journal Article JAMA · March 20, 2013 IMPORTANCE: Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. OBJECTIVE: To investigate whether aliskiren, a direct renin inhibitor, when added to standard ther ... Full text Link to item Cite

Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Journal Article Heart Fail Rev · March 2013 The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The ... Full text Link to item Cite

Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Journal Article Am J Cardiol · February 15, 2013 Lower cholesterol levels are associated with worse outcomes in patients with chronic heart failure (HF) and have been shown to predict in-hospital mortality. The relation between lipid profile and postdischarge outcomes in patients hospitalized for worseni ... Full text Link to item Cite

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.

Journal Article Am Heart J · February 2013 BACKGROUND: Systolic blood pressure (SBP) is related to the pathophysiologic development and progression of heart failure (HF) and is inversely associated with adverse outcomes during hospitalization for HF (HHF). The prognostic value of SBP after initiati ... Full text Link to item Cite

The disconnect between phase II and phase III trials of drugs for heart failure.

Journal Article Nat Rev Cardiol · February 2013 Hospitalization for heart failure (HF) is a clinical entity associated with high postdischarge morbidity and mortality, yet few therapies are available to improve outcomes in patients with this condition. In the past decade, large phase III studies of HF t ... Full text Link to item Cite

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Journal Article Circ Heart Fail · January 2013 BACKGROUND: Arginine vasopressin (AVP) levels are elevated in proportion to heart failure severity and are associated with higher cardiovascular mortality in ambulatory patients. However, the relationship between baseline and trends in AVP with outcomes in ... Full text Link to item Cite

Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Journal Article Am J Cardiol · December 1, 2012 Monocytes play a critical role in the pathophysiology of heart failure (HF), but few studies have evaluated the prognostic implications of an increased monocyte count in patients with HF and reduced ejection fraction (EF). The Efficacy of Vasopressin Antag ... Full text Link to item Cite

Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Journal Article Circ Heart Fail · November 2012 BACKGROUND: Low lymphocyte count has been shown to be an independent prognostic marker in heart failure (HF) in the outpatient setting. Limited data exist regarding whether relative lymphocyte count correlates with postdischarge outcomes in patients hospit ... Full text Link to item Cite

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.

Journal Article Eur J Heart Fail · September 2012 AIMS: Cinaciguat (BAY 58-2667) is a soluble guanylate cyclase (sGC) activator that, in a previous study among patients with acute heart failure syndromes (AHFS), improved pulmonary capillary wedge pressure (PCWP) at the expense of significant hypotension a ... Full text Link to item Cite